Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on...

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Cognitive deficits are a core symptom of schizophrenia, impacting functional outcomes.
• Antipsychotic medications, like risperidone (RIS), are crucial for managing psychosis but their effect on cognition requires further elucidation.
• Limited data exists on the relationship between plasma risperidone concentration and cognitive task performance.

Purpose of the Study:

• To investigate the correlation between plasma concentrations of risperidone (RIS) and its active metabolite 9-hydroxy-risperidone (9-OH-RIS) and performance on the Continuous Performance Test (CPT).
• To provide insights for rational dosage titration of risperidone in schizophrenic patients.

Main Methods:

• Assessed 10 schizophrenia patients (4 male, 6 female) on risperidone (RIS) for over 1 year.
• Measured steady-state plasma concentrations of RIS and 9-OH-RIS using liquid chromatography-tandem mass spectrometry.
• Evaluated psychopathology, extrapyramidal symptoms (EPS), and Continuous Performance Test (CPT) performance.

Main Results:

• A significant negative correlation was observed between CPT performance and plasma concentrations of RIS, 9-OH-RIS, and the combined active moiety (RIS + 9-OH-RIS).
• Both RIS and 9-OH-RIS demonstrated an impact on the cognitive performance of patients with schizophrenia.
• Higher drug concentrations were associated with poorer CPT performance.

Conclusions:

• Plasma concentrations of risperidone and its active metabolite are associated with impaired cognitive performance in schizophrenia.
• These findings suggest that both parent drug and metabolite levels influence cognitive function.
• Further studies are warranted to identify optimal plasma concentrations for maximizing cognitive benefits in patients treated with risperidone.